Our STN: BL 125614/1131

SUPPLEMENT APPROVAL
COMPARABILITY PROTOCOL
July 16, 2025

GlaxoSmithKline Biologicals
Attention: William Hoffner
14200 Shady Grove Road
VR1500
Rockville, MD 20850-7464

Dear Mr. Hoffner:

We have approved your request received December 19, 2024, to supplement your Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for Zoster Vaccine Recombinant, Adjuvanted (SHINGRIX) to include a liquid formulation of SHINGRIX presented in prefilled syringes, referred to as "gE/AS01B Liquid," that is manufactured (formulated and filled) at the GlaxoSmithKline Biologicals SA facility in (b) (4), Belgium.

DATING PERIOD

The dating period for the liquid formulation of SHINGRIX, gE/AS01B Liquid, in prefilled syringes shall be 36 months from the date of manufacture when stored at 2°C to 8°C. The date of manufacture shall be defined as the date of final filling of the formulated product. Following the final sterile filtration, no reprocessing/reworking is allowed without prior approval from the Agency.

COMPARABILITY PROTOCOLS

This approval includes comparability protocols for the following:

Under 21 CFR 601.12(e), approval of a comparability protocol may justify a reduced reporting category for a particular change. In your annual report (21 CFR 601.12(d)), you should report information confirming that the changes below meet the requirements specified in your approved comparability protocols. Include the information described in 21 CFR 601.12(d)(3).

- Qualification of new in-house reference standard batch for Potency gE by (b) (4)
- Qualification of new in-house reference standard batch for QS-21-(b) (4) test by (b) (4)
- Qualification of new in-house reference standard batch for QS-21 Content by (b) (4)

- Qualification of new in-house reference standard batch for MPL Content by (b) (4)
- Qualification of new internal control batch for: Relative abundance of the gE primary sequence by (b) (4), Protein content by (b) (4), Purity gE antigen by (b) (4)
- Qualification of new internal control batch for: Potency gE by (b) (4)
- Qualification of new internal control batch for: Polysorbate 80 content by (b) (4) and QS-21 content by (b) (4)
- Qualification of new internal control batch for: sucrose content by (b) (4)
- Qualification of new internal control batch for: MPL Content by (b) (4)
- Qualification of new internal Control batch for: (b) (4) by (b) (4)
- Qualification of new internal control batch for: DOPC content by (b) (4) and Cholesterol content by (b) (4)
- Qualification of new internal control batch for: (b) (4) content by (b) (4)

Under 21 CFR 601.12(e), approval of a comparability protocol may justify a reduced reporting category for a particular change. You should report information confirming that the change below meets the requirements specified in your approved comparability protocol as a **Supplement – Changes Being Effected in 30 Days** (21 CFR 601.12(c)). You should include the information described in 21 CFR 601.12 (b)(3) in this supplement. Although you may distribute the product made using this change 30 days after FDA receives the supplement, continued use of the change will be subject to our final approval of the supplement.

- Change management protocol for the implementation of sterile filtration at the point of filling (POFF) in the (b) (4) manufacturing facility

You should report information confirming that the change below meets the requirements specified in your approved comparability protocol as a **Prior Approval Supplement** (21 CFR 601.12(b)). You should include the information described in 21 CFR 601.12 (b)(3) in this supplement. Subsequent to the approval of your Prior Approval Supplement, you may distribute the product made using this change.

- Change management protocol for the implementation of an additional manufacturing (formulation, filling and visual Inspection) site at the (b) (4) facility for gE/AS01B Liquid

LABELING

We hereby approve the draft content of labeling: Package Insert submitted under amendment 14, dated April 30, 2025, and the draft carton and container labels submitted under amendment 13, dated April 16, 2025.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the Package Insert submitted on April 30, 2025. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELS

Please electronically submit final printed carton and container labels identical to the carton and container labels submitted on April 16, 2025, according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications* at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-certain-human-pharmaceutical-product-applications.

All final labeling should be submitted as Product Correspondence to this BLA, STN BL 125614, at the time of use and include implementation information on Form FDA 356h.

ADVERTISING AND PROMOTIONAL LABELING

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

For each pending supplemental application for this BLA that includes proposed revised labeling, please submit an amendment to update the proposed revised labeling with the changes approved today.

We will include information contained in the above-referenced supplement in your BLA file.

Sincerely,

Jerry P. Weir, Ph.D.
Director
Division of Viral Products
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research